Klinikum Coburg GmbH
- Address
- lock Available on a paid plan
Klinikum Coburg GmbH - Cardiovascular and Metabolic Research Center
Klinikum Coburg GmbH is a distinguished medical research institution with a strong focus on cardiovascular disease prevention and management. The center demonstrates expertise in innovative interventional cardiology techniques and precision medicine approaches, including novel therapies for heart failure, atrial fibrillation management, and advanced lipid-lowering strategies. Their research portfolio emphasizes both cutting-edge interventional procedures and comprehensive pharmaceutical trials aimed at reducing cardiovascular risk.
- Hypertension management including renal denervation and innovative neurolysis techniques
- Heart failure therapeutics and cardiac biomarker optimization
- Lipid metabolism disorders and lipoprotein(a)-targeted cardiovascular prevention
- Atrial fibrillation ablation and post-procedural stroke prevention strategies
The center's research extends beyond cardiovascular medicine to include oncology, particularly in the area of circulating tumor DNA (ctDNA) analysis for early-stage colorectal cancer. This multidisciplinary approach demonstrates their commitment to precision medicine and biomarker-guided treatment decisions. Their cardiovascular research portfolio is particularly robust, investigating everything from elevated lipoprotein(a) as a cardiovascular risk factor to optimal anticoagulation strategies following catheter ablation procedures, positioning Klinikum Coburg as a comprehensive center for cardiovascular disease prevention and treatment innovation.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 therapeutic areas and 15 of 44 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 44 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
lock +9 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novartis Pharma AG3trials
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Klinikum Coburg GmbH
lock Showing 1 of 17 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active-Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | Janssen Cilag International | Phase III | Not Recruiting | Aug 2023 | — |
IMP list
lock Showing 1 of 44 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Apixaban | 2 | Unknown | 2023-08-23 | 2024-01-29 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.